Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)

Phase 1

Completed

Conditions: Type1 Diabetes Mellitus

Interventions: Device: AID System
Drug: Insulin Lispro

First Posted Date: 2017-12-08

Last Posted Date: 2018-03-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT03367390

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Renton, Washington, United States

A Study of LY3209590 in Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3209590
Drug: Insulin Glargine

First Posted Date: 2017-12-08

Last Posted Date: 2018-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT03367377

Locations: 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
🇨🇦
LMC Endocrinology Centres Ltd., Toronto, Ontario, Canada

A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Ixekizumab
Drug: Placebo

First Posted Date: 2017-12-06

Last Posted Date: 2021-06-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 438

Registration Number: NCT03364309

Locations: 🇨🇳
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Nanjing, China
🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

and more 14 locations

A Study of Dulaglutide in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dulaglutide (Reference)
Drug: Dulaglutide (Test)

First Posted Date: 2017-12-06

Last Posted Date: 2019-07-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT03363906

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor
Non Small Cell Lung Cancer
Renal Cell Carcinoma
Triple Negative Breast Cancer

Interventions: Drug: LY3381916
Drug: LY3300054

First Posted Date: 2017-11-17

Last Posted Date: 2020-06-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT03343613

Locations: 🇺🇸
IU Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇫🇷
Gustave Roussy, Villejuif Cedex, France

and more 9 locations

A Study of LY3375880 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo IV
Drug: LY3375880 IV
Drug: Placebo SC
Drug: LY3375880 SC

First Posted Date: 2017-11-17

Last Posted Date: 2018-12-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT03343587

Locations: 🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States

A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: Insulin Lispro
Biological: LY900014

First Posted Date: 2017-11-14

Last Posted Date: 2020-06-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT03341312

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany

A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Biological: Insulin Lispro
Biological: LY900014

First Posted Date: 2017-11-14

Last Posted Date: 2020-05-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT03341299

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany

A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: Nasal Glucagon
Drug: Intramuscular Glucagon

First Posted Date: 2017-11-13

Last Posted Date: 2019-09-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT03339453

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: LY2963016
Drug: Lantus®
Drug: Insulin Lispro

First Posted Date: 2017-11-09

Last Posted Date: 2021-03-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 272

Registration Number: NCT03338023

Locations: 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳
Guangdong Province People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Wu Han Tongji Hospital, Wu Han, Hu Bei, China

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy